{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:59:38Z","timestamp":1774407578706,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)\/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.<\/jats:p>","DOI":"10.1186\/s12933-023-01993-3","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T15:02:24Z","timestamp":1697209344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop"],"prefix":"10.1186","volume":"22","author":[{"given":"Antonio","family":"Ceriello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Brosius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Kellerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Koob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nebojsa","family":"Lalic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Prashant","family":"Nedungadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Parkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne Huey-Herng","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Standl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per Olav","family":"Vandvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Taskforce of the Guideline Workshop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"1993_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, International Diabetes Federation. 2021. https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/. Accessed 31 8 Jan 2023."},{"key":"1993_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2337\/dc19-2165","volume":"43","author":"G Ferrannini","year":"2020","unstructured":"Ferrannini G, de Bacquer D, De Backer G, on behalf of the EUROASPIRE V team, et al. Screening for glucose perturbations and risk factor management in dysglycaemic patients with coronary artery disease - a persistent challenge in need of substantial improvement. A report from EUROASPIRE V. Diabetes Care. 2020;43:726\u201333.","journal-title":"Diabetes Care"},{"key":"1993_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.diabres.2017.12.004","volume":"137","author":"K Khunti","year":"2018","unstructured":"Khunti K, Ceriello A, Cos X, De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2018;137:137\u201348. https:\/\/doi.org\/10.1016\/j.diabres.2017.12.004.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1993_CR4","doi-asserted-by":"publisher","first-page":"e14766","DOI":"10.1111\/dme.14766","volume":"39","author":"R Prigge","year":"2022","unstructured":"Prigge R, McKnight JA, Wild SH, et al. International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabet Med. 2022;39(5):e14766. https:\/\/doi.org\/10.1111\/dme.14766.","journal-title":"Diabet Med"},{"issue":"6","key":"1993_CR5","doi-asserted-by":"publisher","first-page":"e26180","DOI":"10.7759\/cureus.26180","volume":"14","author":"SA Bin Rakhis Sr","year":"2022","unstructured":"Bin Rakhis Sr SA, AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic control for type 2 diabetes mellitus patients: a systematic review. Cureus. 2022;14(6):e26180. https:\/\/doi.org\/10.7759\/cureus.26180.","journal-title":"Cureus"},{"key":"1993_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12933-023-01788-6","volume":"2023","author":"O Schnell","year":"2022","unstructured":"Schnell O, Battelino T, Bergenstal RM, Summit CVOT, et al. Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol. 2022;2023:22. https:\/\/doi.org\/10.1186\/s12933-023-01788-6.","journal-title":"Cardiovasc Diabetol"},{"key":"1993_CR7","doi-asserted-by":"publisher","first-page":"108870","DOI":"10.1016\/j.diabres.2021.108870","volume":"177","author":"N Marx","year":"2021","unstructured":"Marx N, Ryden L, Brosius F, et al. Towards living guidelines on cardiorenal outcomes in diabetes: a pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Res Clin Pract. 2021;177:108870. https:\/\/doi.org\/10.1016\/j.diabres.2021.108870.","journal-title":"Diabetes Res Clin Pract"},{"key":"1993_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"1993_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"issue":"13","key":"1993_CR10","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.3390\/molecules27134315","volume":"27","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022;27(13):4315. https:\/\/doi.org\/10.3390\/molecules27134315.","journal-title":"Molecules"},{"issue":"6","key":"1993_CR11","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345. https:\/\/doi.org\/10.1001\/jama.2022.0078.","journal-title":"JAMA"},{"issue":"6","key":"1993_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777.","journal-title":"Eur Heart J"},{"issue":"1","key":"1993_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103\u201311. https:\/\/doi.org\/10.1007\/s11739-016-1583-7.","journal-title":"Intern Emerg Med"},{"key":"1993_CR14","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41433-022-01943-5","volume":"36","author":"MR Phillips","year":"2022","unstructured":"Phillips MR, Steel DH, Wykoff CC, et al. A clinician\u2019s guide to network meta-analysis. Eye. 2022;36:1523\u20136. https:\/\/doi.org\/10.1038\/s41433-022-01943-5.","journal-title":"Eye"},{"key":"1993_CR15","doi-asserted-by":"publisher","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of pharmacotherapy for type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068.","journal-title":"BMJ"},{"key":"1993_CR16","unstructured":"MAGIC Evidence Ecosystem Foundation. https:\/\/magicevidence.org. Accessed 1 Feb 2023."},{"key":"1993_CR17","unstructured":"MAGIC Evidence Ecosystem Foundation. MATCH-IT tool. https:\/\/matchit.magicevidence.org\/230125dist-diabetes\/#!\/. Accessed 1 Feb 2023."},{"key":"1993_CR18","doi-asserted-by":"publisher","first-page":"108092","DOI":"10.1016\/j.diabres.2020.108092","volume":"162","author":"N Marx","year":"2020","unstructured":"Marx N, Ryd\u00e9n L, Brosius F, et al. Proceedings of the Guideline Workshop 2019 - Strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases. Diabetes Res Clin Pract. 2020;162:108092. https:\/\/doi.org\/10.1016\/j.diabres.2020.108092.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7454","key":"1993_CR19","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, GRADE Working Group, et al. Grading quality of evidence and strength of recommendations. BMC. 2004;328(7454):1490.","journal-title":"BMC"},{"issue":"7","key":"1993_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength. J Clin Epidemiol. 2013;66(7):726\u201335.","journal-title":"J Clin Epidemiol"},{"key":"1993_CR21","doi-asserted-by":"publisher","first-page":"i2089","DOI":"10.1136\/bmj.i2089","volume":"353","author":"P Alonso-Coello","year":"2016","unstructured":"Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089.","journal-title":"BMJ"},{"issue":"7652","key":"1993_CR22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336(7652):1049\u201351.","journal-title":"BMJ"},{"issue":"7","key":"1993_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719\u201325.","journal-title":"J Clin Epidemiol"},{"key":"1993_CR24","doi-asserted-by":"publisher","first-page":"m3900","DOI":"10.1136\/bmj.m3900","volume":"371","author":"R Brignardello-Petersen","year":"2020","unstructured":"Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ. 2020;371:m3900. https:\/\/doi.org\/10.1136\/bmj.m3900.","journal-title":"BMJ"},{"key":"1993_CR25","doi-asserted-by":"publisher","first-page":"e056400","DOI":"10.1136\/bmjopen-2021-056400","volume":"12","author":"MR Phillips","year":"2022","unstructured":"Phillips MR, Sadeghirad B, Busse JW, et al. Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study. BMJ Open. 2022;12:e056400. https:\/\/doi.org\/10.1136\/bmjopen-2021-056400.","journal-title":"BMJ Open"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01993-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01993-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01993-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T13:25:39Z","timestamp":1700486739000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01993-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1993"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01993-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"17 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have provided their consent for publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All other authors declared no potential competing interest relevant to the authorship and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}